The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis

References

• Tefferi A. Myelodysplastic syndromes—many new drugs, little therapeutic progress. Mayo Clin Proc. 2010;85(11):1042–1045.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Shallis RM, Wang R, et al. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1–15.
   PubMed Web of Science ®Google Scholar
• Surveillance E, Program ER. SEER* Stat Database: incidence‐SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov. 2017 Sub (2000–2015)‐Linked To County Attributes‐Total US, 1969–2016 Counties; 2017.
   Google Scholar
• Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Co-Operative Group. Br J Haematol. 1976;33(4):451–458.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951.
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032.
   PubMed Web of Science ®Google Scholar
• Keng MK, Sekeres MA. The race for survival in myelodysplastic syndromes. Leuk Lymphoma. 2013;54(2):219–220.
   PubMed Web of Science ®Google Scholar
• Bowen DT, et al. Etiology and epidemiology of MDS. In: Deeg HJ, Bowen DT, Gore SD, editors. Hematologic malignancies: myelodysplastic syndromes. Berlin, Heidelberg: Springer; 2006. p. 15–22.
   Google Scholar
• Shallis RM, Ahmad R, Zeidan AM. The genetic and molecular pathogenesis of myelodysplastic syndromes. Eur J Haematol. 2018;101(3):260–271.
   PubMed Web of Science ®Google Scholar
• Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536–1542.
   PubMed Web of Science ®Google Scholar
• Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45–52.
   PubMed Web of Science ®Google Scholar
• Bierenbaum J, Davidoff AJ, Ning Y, et al. Racial differences in presentation, referral and treatment patterns and survival in adult patients with acute myeloid leukemia: a single-institution experience. Leuk Res. 2012;36(2):140–145.
   PubMed Web of Science ®Google Scholar
• Schwartz K, Powell IJ, Underwood W 3rd, et al. Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. Urology. 2009;74(6):1296–1302.
   PubMed Web of Science ®Google Scholar
• Settle K, Posner MR, Schumaker LM, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res. 2009;2(9):776–781.
   PubMed Web of Science ®Google Scholar
• Morris GJ, Mitchell EP. Higher incidence of aggressive breast cancers in African-American women: a review. J Natl Med Assoc. 2008;100(6):698–702.
   PubMed Web of Science ®Google Scholar
• Zandberg DP, Hendrick F, Vannorsdall E, et al. Tertiary center referral patterns for patients with myelodysplastic syndrome are indicative of age and race disparities: a single-institution experience. Leuk Lymphoma. 2013;54(2):304–309.
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Matacia-Murphy GM, Al Ali NH, et al. Outcome of patients with myelodysplastic syndromes in the veterans administration population. Leuk Res. 2010;34(1):59–62.
   PubMed Web of Science ®Google Scholar
• Komrokji R. Myelodysplastic syndromes: a view from where the sun rises and where the sun sets. Leuk Res. 2006;30(9):1067–1068.
   PubMed Web of Science ®Google Scholar
• Matsuda A, Germing U, Jinnai I, et al. Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes. Leuk Res. 2010;34(8):974–980.
   PubMed Web of Science ®Google Scholar
• Wang R, Gross CP, Frick K, et al. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leuk Res. 2012;36(11):1370–1375.
   PubMed Web of Science ®Google Scholar
• NIH U. National Cancer Institute, Division of Cancer Control and Population Sciences. Surveillance, Epidemiology, and End Results Program 1975–2000; 2000.
   Google Scholar
• Zeidan AM, Stahl M, Hu X, et al. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood. 2018;131(7):818–821.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Zhu W, Stahl M, et al. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leuk Lymphoma. 2019;60(13):3181–3187.
   PubMed Web of Science ®Google Scholar
• Murthy GSG, Szabo A, Michaelis L, et al. Improving outcomes of acute promyelocytic leukemia in the current era: analysis of the SEER database. J Natl Compr Canc Netw. 2020;18(2):169–175.
   PubMed Web of Science ®Google Scholar
• Sridharan A, Jain R, Bachhuber MA, et al. Epidemiologic study of myelodysplastic syndromes in a multiethnic, inner city cohort. Exp Hematol Oncol. 2014;3:22.
   PubMedGoogle Scholar
• Nolte F, Schumann C, Klein S, et al. Characteristics of MDS patients seen at private practices differ significantly from those treated at university hospitals in Germany. J Cancer Res Clin Oncol. 2012;138(6):953–957.
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Strupp C, Aivado M, et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol. 2006;24(34):5358–5365.
   PubMed Web of Science ®Google Scholar
• Marisavljevic D, Savic A, Zeremski V, et al. Myelodysplastic syndromes in adults aged less than 50 years: incidence and clinicopathological data. J Buon. 2014;9(4):999–1005.
   Google Scholar